The 17 most recent market catalysts affecting $CMPS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 22, 2026
Corporate Catalyst
Bearish
Impact 95
Compass Therapeutics shares are trading lower after the company announced that the FDA recommended it conduct a trial demonstrating a survival benefit before proceeding with a Biologics License Application submission for tovecimig in patients with previously treated, advanced biliary tract cancer
This headline represents a major negative catalyst for Compass Therapeutics. The FDA's recommendation for a survival benefit trial is a significant hurdle, indicating that the curr…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 85
Compass Pathways shares are trading higher after the company announced the topline 52-week results from its Phase 3 COMP005 trial of COMP360 for treatment-resistant depression TRD.
The positive topline 52-week results from Compass Pathways' Phase 3 COMP005 trial for COMP360 in treatment-resistant depression (TRD) are a major corporate catalyst. This news dire…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 85
Compass Pathways’ Psilocybin Treatment Shows Lasting Benefits in Treatment-Resistant Depression
Compass Pathways released promising 52-week data for its psilocybin treatment, COMP360, for treatment-resistant depression. The results demonstrate sustained efficacy and a favorab…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 85
Compass Pathways Shares Topline 52-week Results (Part C) From Its Phase 3 COMP005 Trial Of Comp360 For Treatment-Resistant Depression, Showing Additional Benefit Extending Durability Out To 1 Year
Compass Pathways (CMPS) has released encouraging 52-week data from its COMP005 trial for COMP360, showing sustained efficacy in treating treatment-resistant depression (TRD) with a…
Sep 8, 2026
Corporate Catalyst
Neutral
Impact 55
Compass Pathways To Participate In Psych Congress 2026 With New Educational Campaign Regarding Treatment-Resistant Depression
Compass Pathways is announcing its participation in Psych Congress 2026, where it will launch a new educational campaign, 'Change the Tune in TRD,' aimed at U.S. healthcare profess…
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 75
President Trump Say In A Social Media Post That The University Of Miami Shared Its 1994 Ibogaine Investigational New Drug Application With The Government, Which Will Help Accelerate Development As A Medical Treatment In The U.S.
The headline indicates a significant step towards potentially legalizing and commercializing Ibogaine for medical use in the U.S. This could create a new therapeutic market, benefi…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Overweight on Compass Pathways, Raises Price Target to $18
Morgan Stanley analyst Judah Frommer has maintained an 'Overweight' rating on Compass Pathways (CMPS) and slightly increased the price target from $17 to $18. This action signals c…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Maintains Outperform on Compass Pathways, Lowers Price Target to $21
RBC Capital analyst Leonid Timashev maintained an 'Outperform' rating on Compass Pathways (CMPS), signaling continued confidence in the company's long-term prospects. However, the …
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
B. Riley Securities Maintains Buy on Compass Pathways, Raises Price Target to $22
B. Riley Securities analyst Madison El-Saadi has maintained a 'Buy' rating on Compass Pathways (CMPS) and raised the price target from $17 to $22. This indicates increased confiden…
Aug 5, 2026
Corporate Catalyst
Neutral
Impact 55
Compass Pathways Files Prospectus For Offering Mixed Shelf; Terms Undisclosed
Compass Pathways (CMPS) has filed a mixed shelf prospectus, which is a common regulatory step allowing a company to offer different types of securities (e.g., common stock, preferr…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 75
COMPASS Pathways shares are trading higher after the company reported better-than-expected Q2 adjusted EPS results.
This headline signals a strong positive corporate catalyst for COMPASS Pathways, driven by better-than-expected earnings. Such beats often lead to significant short-term price appr…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 75
UPDATE: Compass Pathways Q2 Adj. EPS $(0.36) Beats $(0.40) Estimate. (Adj EPS excludes Fair value change of warrant liabilities)
Compass Pathways (CMPS) announced Q2 adjusted EPS of $(0.36), which was better than the analyst consensus of $(0.40) and an improvement from $(0.41) in the same period last year. T…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 95
Compass Pathways Q2 EPS $(1.88) Misses $(0.37) Estimate
Compass Pathways announced Q2 earnings per share of $(1.88), which missed analyst consensus estimates of $(0.37) by a substantial 408.11%. This represents a 358.54% decrease over l…
Jul 27, 2026
Corporate Catalyst
Neutral
Impact 55
Wells Fargo Initiates Coverage On Compass Pathways with Equal-Weight Rating, Announces Price Target of $13
Wells Fargo analyst Benjamin Burnett initiated coverage on Compass Pathways (CMPS), a biotechnology company, with an 'Equal-Weight' rating and a $13 price target. This event is sig…
Jul 16, 2026
Corporate Catalyst
Neutral
Impact 65
'Federal Officials Investigate Online Ketamine Sellers to Curb At-Home Use' - WSJ Exclusive
The WSJ exclusive reveals that federal officials are actively investigating online ketamine sellers, aiming to curb at-home use. This matters because it signals a significant shift…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 75
Compass Pathways shares are trading higher after the company announced the publication of a post-hoc analysis of support methods used in an open-label Phase 2 study of investigational COMP360 synthetic psilocybin treatment in patients with post-traumatic stress disorder.
This headline represents a significant corporate catalyst for Compass Pathways. The publication of positive post-hoc analysis, even from an open-label study, provides additional sc…
Jul 16, 2026
Corporate Catalyst
Neutral
Impact 55
Compass Pathways Announces Publication Of Post-Hoc Analysis Of Support Methods In Phase 2 Study Of Investigational COMP360 Synthetic Psilocybin Treatment
Compass Pathways announced the publication of a post-hoc analysis of support methods in its Phase 2 COMP360 study for PTSD. This analysis is significant because it demonstrates tha…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.